Zobrazeno 1 - 10
of 76
pro vyhledávání: '"Balaji Agoram"'
Prior to entering clinical testing, a new molecular entity must first undergo a series of rigorous scientific assessments. These include pharmacologic evaluations of safety and efficacy, toxicology testing under carefully controlled conditions, and t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::70ce5e47c1d2cdbb2cdad0edb404dbef
https://doi.org/10.1016/b978-0-12-819869-8.00031-8
https://doi.org/10.1016/b978-0-12-819869-8.00031-8
Autor:
Darrell R. Abernethy, Balaji Agoram, John M. Allen, Mark E. Arnold, Arthur J. Atkinson, Thomas J. Bateman, Kimberly Bergman, Brian Booth, David W. Boulton, Robert A. Branch, Gilbert J. Burckart, Mary Buschmann, Owen Carmichael, Christine Chamberlain, Ligong Chen, Charles E. Daniels, Promi Das, Jana G. Delfino, John N. Van Den Anker, Albert W. Dreisbach, Michael Dyszel, Justin C. Earp, M. Khair ElZarrad, Osatohanmwen J. Enogieru, Elimika Pfuma Fletcher, David M. Foster, Marilynn C. Frederiksen, Aleksandra Galetin, Pamela D. Garzone, Kathleen M. Giacomini, Megan A. Gibbs, Jack A Gilbert, Danijela Gnjidic, Charles T. Gombar, Denis M. Grant, Charles Grudzinskas, Bengt Hamren, Nicholas H.G. Holford, Shiew-Mei Huang, Renee Iacona, Nina Isoherranen, Denise Jin, Bridgette L. Jones, Gregory L. Kearns, Cindy Kortepeter, Elizabeth Kunkoski, S.W. Johnny Lau, Christopher Leptak, Juan J.L. Lertora, Lawrence J. Lesko, Jiang Liu, Qi Liu, Rajanikanth Madabushi, Raymond Miller, Diane R. Mould, Monica Muñoz, Thomas D. Nolin, Robert Joseph Noveck, R. Scott Obach, Michael Pacanowski, Mary F. Paine, Carl C. Peck, Anuradha Ramamoorthy, A. David Rodrigues, Malcolm Rowland, Chandrahas G. Sahajwalla, Martina Dagmar Sahre, Robert N. Schuck, Khushboo Sharma, Tristan Sissung, Catherine S. Stika, Chris H. Takimoto, Helen Tomkinson, Jack Uetrecht, Paolo Vicini, Karen D. Vo, John A. Wagner, Yaning Wang, Yow-Ming C. Wang, Peter G. Wells, Michael J. Wick, Sook Wah Yee, Ophelia Yin, Nathalie K. Zgheib, Lei Zhang, Hao Zhu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::848d2065918d75dffbea67f6015e7476
https://doi.org/10.1016/b978-0-12-819869-8.09990-0
https://doi.org/10.1016/b978-0-12-819869-8.09990-0
Autor:
Lorin Roskos, Neang Ly, Yanan Zheng, Jane R. Parnes, Janet M. Griffiths, Rene van der Merwe, Balaji Agoram
Publikováno v:
Journal of clinical pharmacologyReferences. 61(7)
Tezepelumab is a human monoclonal antibody that blocks thymic stromal lymphopoietin, an epithelial cytokine involved in asthma pathogenesis. In the phase 2b PATHWAY study (ClinicalTrials.gov identifier: NCT02054130), tezepelumab significantly reduced
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ae232e20b612adfec02c979a6dd966a
https://pubmed.ncbi.nlm.nih.gov/33368307
https://pubmed.ncbi.nlm.nih.gov/33368307
Autor:
Nicholas J. White, Balaji Agoram, Diane V. Doughty, René van der Merwe, Xiaobai Li, Meena Jain, Corbin Clawson
Publikováno v:
International Journal of Clinical Pharmacology and Therapeutics
Objective Tralokinumab, administered as two 1-mL subcutaneous injections every 2 weeks, at the target dose 300 mg, has been shown to improve lung function in patients with asthma. This study evaluated the pharmacokinetic (PK) and tolerability profile
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::371f483194c5a4c2fa76651cf32e8b4a
https://doi.org/10.5414/cp203023
https://doi.org/10.5414/cp203023
Autor:
Jie Liu, Shirley Mihardja, Irving L. Weissman, Ravindra Majeti, Jens-Peter Volkmer, Balaji Agoram, Kavitha Sompalli, Sharline Chen, Seethu Xavy, Timothy S Choi, Dongdong Feng
Publikováno v:
JCI Insight
The CD47/signal regulatory protein α (Cd47/SIRPα)interaction provides a macrophage immune checkpoint pathway that plays a critical role in cancer immune evasion across multiple cancers. Here, we report the engineering of a humanized anti-SIRPα mon
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d47165cdac3a638bd37ce609e8658616
https://pubmed.ncbi.nlm.nih.gov/32427583
https://pubmed.ncbi.nlm.nih.gov/32427583
Autor:
Susan S. Prohaska, Rhonda Aoki, Timothy J. O'Rourke, Sreenivasa R Chandana, Amita Patnaik, Mark P. Chao, Jie Huang, Matthew Axt, Nehal Lakhani, Kyriakos P. Papadopoulos, Muralidhar Beeram, Sukhmani K. Padda, Dana Supan, Heather A. Wakelee, Victor M. Villalobos, Chris H. Takimoto, Jens-Peter Volkmer, George A. Fisher, Irving L. Weissman, Sujata Narayanan, Ravindra Majeti, Branimir I. Sikic, Mark D. Pegram, Balaji Agoram, Sumit A. Shah, A. Dimitrios Colevas, James Y. Chen, Drew W. Rasco, Jie Liu, Maureen Howard
Publikováno v:
J Clin Oncol
PURPOSE To evaluate the safety, pharmacokinetics, and pharmacodynamics of Hu5F9-G4 (5F9), a humanized IgG4 antibody that targets CD47 to enable phagocytosis. PATIENTS AND METHODS Adult patients with solid tumors were treated in four cohorts: part A,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::582789961410d3b42881be3bad76c3f0
https://europepmc.org/articles/PMC7186585/
https://europepmc.org/articles/PMC7186585/
Autor:
Tamara J. van Steeg, Nazzareno Dimasi, Kris Sachsenmeier, Balaji Agoram, Kirsten Riber Bergmann
Publikováno v:
mAbs
Targeting multiple receptors with bispecific antibodies is a novel approach that may prevent the development of resistance to cancer treatments. Despite the initial promise, full clinical benefit of this technology has yet to be realized. We hypothes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04c8afa6dc1240df9714b4a1bb81cb72
https://doi.org/10.1080/19420862.2016.1141160
https://doi.org/10.1080/19420862.2016.1141160
Autor:
Mark P. Chao, Roy Louis Maute, Chris H. Takimoto, ChaoYu Jin, Balaji Agoram, David A. Sallman
Publikováno v:
Journal of Clinical Oncology. 38:e15098-e15098
e15098 Background: Magrolimab (Hu5F9-G4) is a monoclonal IgG4 antibody that binds to CD47 receptor and blocks its interaction with SIRPA, thereby enabling tumor cell phagocytosis and activation of an anti-tumor T-cell response. Magrolimab has shown e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7811f00830b13ba3868e5a69fe24e8dd
https://doi.org/10.1200/jco.2020.38.15_suppl.e15098
https://doi.org/10.1200/jco.2020.38.15_suppl.e15098
Autor:
Roy Louis Maute, Amita Patnaik, Balaji Agoram, Yan V. Wang, Isagani Chico, Cathy Eng, Mark P. Chao, Philip A. Philip, Jens-Peter Volkmer, Peter J. O'Dwyer, J. Randolph Hecht, Tina M Ippolito, Chris H. Takimoto, Johanna C. Bendell, Benny Johnson, Nehal Lakhani, George A. Fisher, Adel Kardosh
Publikováno v:
Journal of Clinical Oncology. 38:114-114
114 Background: Magrolimab (M, Hu5F9-G4) is an antibody targeting CD47, a macrophage “don’t eat me” signal that demonstrates preclinical synergy with cetuximab (C) in refractory KRAS wild type (KRASwt) and KRAS mutant (KRASm) colorectal (CRC) t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5085e07fda6e15add95f932ed66b614e
https://doi.org/10.1200/jco.2020.38.4_suppl.114
https://doi.org/10.1200/jco.2020.38.4_suppl.114
Autor:
Andres Forero, Balaji Agoram, Ian W. Flinn, Nilanjan Ghosh, Ravindra Majeti, Justin Kline, Chris H. Takimoto, Ann S. LaCasce, Graham P. Collins, Jie Huang, Leslie Popplewell, Mark P. Chao, Ranjana H. Advani, Sonali M. Smith, Jens Peter Volkmer, Nancy L. Bartlett, James Y. Chen, Thu Tran, Judith Lynn, Irving L. Weissman, Mark Roschewski
Publikováno v:
N Engl J Med
BACKGROUND: The Hu5F9-G4 (hereafter, 5F9) antibody is a macrophage immune checkpoint inhibitor blocking CD47 that induces tumor-cell phagocytosis. 5F9 synergizes with rituximab to eliminate B-cell non-Hodgkin’s lymphoma cells by enhancing macrophag
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::660570deb02df6b316f7ccb5dea18d75
https://europepmc.org/articles/PMC8058634/
https://europepmc.org/articles/PMC8058634/